Prime Medicine (PRME) Operating Income (2021 - 2026)
Prime Medicine (PRME) posted Operating Income of -$50.7 million for Q1 2026, down 4.21% on a QoQ basis from -$48.6 million in Q4 2025, and up 3.32% year-over-year from -$49.0 million in Q1 2025.
Prime Medicine (PRME) Operating Income (2021 - 2026) Analysis & Trends
Prime Medicine's Operating Income history runs 6 years deep, the most recent figure standing at -$50.7 million for Q1 2026.
- Quarterly Operating Income rose 3.32% year-over-year to -$50.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$206.6 million (changed 0.05% YoY) and the FY2025 annual result came in at -$208.4 million, down 2.91% from the prior year.
- Operating Income was -$50.7 million for Q1 2026 at Prime Medicine, down from -$48.6 million in the prior quarter.
- Across five years, Operating Income topped out at -$19.9 million in Q1 2022 and bottomed at -$68.0 million in Q4 2023.
- A 5-year average of -$46.0 million and a median of -$48.6 million in 2025 frame the typical range for Operating Income.
- Peak annual rise in Operating Income reached 35.6% in 2022, while the deepest fall reached 203.59% in 2022.
- Prime Medicine's Operating Income stood at -$38.7 million in 2022, then slumped by 75.89% to -$68.0 million in 2023, then surged by 35.01% to -$44.2 million in 2024, then dropped by 9.92% to -$48.6 million in 2025, then fell by 4.21% to -$50.7 million in 2026.
- Business Quant data shows PRME's Operating Income at -$50.7 million in Q1 2026, -$48.6 million in Q4 2025, and -$54.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -27.75 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -15.76 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 249.90 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.14 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 642.90 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -32.68 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 394.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -445.22 Mn |
| 10 | Prime Medicine | 524.20 Mn | 524.20 Mn | - | -50.65 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -50.65 Mn |
| Dec 31, 2025 | -48.61 Mn |
| Sep 30, 2025 | -53.97 Mn |
| Jun 30, 2025 | -53.38 Mn |
| Mar 31, 2025 | -52.39 Mn |
| Dec 31, 2024 | -44.22 Mn |
| Sep 30, 2024 | -54.23 Mn |
| Jun 30, 2024 | -55.67 Mn |
| Mar 31, 2024 | -48.34 Mn |
| Dec 31, 2023 | -68.04 Mn |
| Sep 30, 2023 | -51.46 Mn |
| Jun 30, 2023 | -45.26 Mn |
| Mar 31, 2023 | -40.03 Mn |
| Dec 31, 2022 | -38.69 Mn |
| Sep 30, 2022 | -31.66 Mn |
| Jun 30, 2022 | -26.31 Mn |
| Mar 31, 2022 | -19.90 Mn |
| Dec 31, 2021 | -60.08 Mn |
| Sep 30, 2021 | -10.43 Mn |